Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(13)
MIXED(2)
MGCD0103
10 trials
phase_1phase_1_2phase_2
mirati-therapeutics-inc
Gemcitabine
1 trial
phase_1_2
mirati-therapeutics-inc
Azacitidine
1 trial
phase_2
mirati-therapeutics-inc
MGCD290
1 trial
phase_2
methylgene-inc
MGCD0103 & Docetaxel
1 trial
phase_1
mirati-therapeutics-inc
MGCD0103 and Azacitidine
1 trial
phase_2
mirati-therapeutics-inc
6 unique interventions2 categories

Analytics

Trial Phases

Phase 16
Phase 29

Trial Status

Completed8
Terminated5

Role Distribution

Other Roles13

Activity Timeline

Clinical Trials (13)

NCT00323934Phase 1Completed
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Non Hodgkin's LymphomaTumors
Studydirector
NCT00324129Phase 1Completed
A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes
LeukemiaMyelodysplastic Syndromes
Studydirector
NCT00324194Phase 1Completed
A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
LeukemiaMyelodysplastic Syndromes
Studydirector
NCT00324220Phase 1/2Completed
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Studydirector
NCT00358982Phase 2Terminated
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Hodgkin's Lymphoma
Studydirector
NCT00359086Phase 2Completed
Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
Lymphoma
Studydirector
NCT00372437Phase 1/2Completed
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
Tumors
Studydirector
NCT00374296Phase 2Terminated
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
Myelodysplastic SyndromesMyelogenous Leukemia, Acute
Studydirector
NCT00431873Phase 2Completed
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Lymphocytic Leukemia, Chronic
Studydirector
NCT00511576Phase 1Terminated
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Breast CancerGastric CancerLung Cancer+5 more
Studydirector

Showing 10 of 13 trials

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Dong-Xin Wang, MD, PhD

Peking University First Hospital

Related
74 trials

Shared therapeutic areas:

Lung CancerNeoplasmsBreast Cancer+2 more
Similarity Score9%

Jorge Cortes, MD

M.D. Anderson Cancer Center

Related
24 trials

Shared therapeutic areas:

LeukemiaLeukemia, Myeloid, AcuteMyelodysplastic Syndromes+1 more
Similarity Score8%

Aminah Jatoi, MD

Mayo Clinic

Related
29 trials

Shared therapeutic areas:

Lung CancerCancer of StomachProstate Cancer+1 more
Similarity Score8%

Tanya Trippett, MD

Memorial Sloan Kettering Cancer Center

Related
13 trials

Shared therapeutic areas:

LymphomaLeukemiaHodgkin Disease+1 more
Similarity Score8%

Zhenfeng Zhang, MD, PhD

Second Affiliated Hospital of Guangzhou Medical University

Related
21 trials

Shared therapeutic areas:

Lung CancerBreast CancerCarcinoma, Non-Small-Cell Lung+1 more
Similarity Score8%

Mark Levine, MD

Ontario Clinical Oncology Group (OCOG)

Related
13 trials

Shared therapeutic areas:

Breast CancerProstate CancerLymphoma+1 more
Similarity Score8%

Areej El-Jawahri, MD

Massachusetts General Hospital

Related
21 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLymphomaMyelodysplastic Syndromes
Similarity Score6%

Lin Shen, MD

Peking University Cancer Hospital & Institute

Related
20 trials

Shared therapeutic areas:

Cancer of StomachBreast CancerLung Cancer
Similarity Score6%

Guillermo Garcia-Manero, MD

M.D. Anderson Cancer Center

Related
18 trials

Shared therapeutic areas:

LeukemiaMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Similarity Score6%

Lizhi Niu, PhD

Fuda Cancer Hospital

Related
31 trials

Shared therapeutic areas:

Breast CancerLung Cancer
Similarity Score4%

Publications (0)

No publications found for this investigator.

Clinical Trials (13)

Showing 13 of 13 trials

NCT00323934Phase 1StudyDirector

Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Non Hodgkin's LymphomaTumors
Completed
NCT00324129Phase 1StudyDirector

A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes

LeukemiaMyelodysplastic Syndromes
Completed
NCT00324194Phase 1StudyDirector

A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

LeukemiaMyelodysplastic Syndromes
Completed
NCT00324220Phase 1/2StudyDirector

A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia

Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Completed
NCT00358982Phase 2StudyDirector

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma
Terminated
NCT00359086Phase 2StudyDirector

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Lymphoma
Completed
NCT00372437Phase 1/2StudyDirector

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

Tumors
Completed
NCT00374296Phase 2StudyDirector

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Myelodysplastic SyndromesMyelogenous Leukemia, Acute
Terminated
NCT00431873Phase 2StudyDirector

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic
Completed
NCT00511576Phase 1StudyDirector

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Breast CancerGastric CancerLung Cancer+5 more
Terminated
NCT00543582Phase 2StudyDirector

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Hodgkin LymphomaNon-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)
Terminated
NCT00666497Phase 2StudyDirector

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
Terminated
NCT01497223Phase 2StudyDirector

MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

Vulvovaginal Candidiasis
Completed

All 13 trials loaded